PV Bulletin

Change to Patient Information and Information for Healthcare Professionals Templates

Swissmedic has updated the templates for Patient Information (PI) and Information for Healthcare Professionals (FI), introducing an optional section for instructions for use.

PV Impact Brief

Urgency: HighConfidence: high

What changed

MAHs must use updated PI/FI templates for new submissions and variations, and incorporate the optional 'Gebrauchsanweisungen' section from 1 July 2026.

Why it matters

This change ensures that safety information and instructions for use are clearly presented, improving readability and user-friendliness for patients and healthcare professionals.

Action needed

MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
revised
Publication date
2026-07-01
Policy change
Swissmedic has updated the templates for Patient Information (PI) and Information for Healthcare Professionals (FI), adding an optional 'Gebrauchsanweisungen' (instructions for use) section to accommodate redesigned barrier-free access websites.

Key changes

New optional section for instructions for use; updated templates must be used for new medicinal product information texts from 1 July 2026.

Affected workflows

Labeling

PV impact

MAHs must use updated PI/FI templates for new submissions and variations to ensure appropriate presentation of safety information and instructions.

View regulator source

Source document details

Exact policy details

Use of updated templates
1 July 2026
Applies to: Applicable for new medicinal product information texts.
The updated Patient information and Information for healthcare professionals for human medicinal products templates must be used from 1 July 2026 for new medicinal product information texts. · p. 1 · High · Source
Responsibility for readability and user-friendliness
Authored by the authorization holder
Applies to: All authorization holders of human medicinal products
The authorisation holder is responsible for ensuring the Patient information and Information for healthcare professionals are readable and user-friendly. · p. 1 · High · Source
Update requirement for existing products
At the earliest opportunity
Applies to: Medicinal products already authorized
Swissmedic requests authorisation holders for medicinal products whose Patient information and/or Information for healthcare professionals include instructions for use at the end of the document to update the relevant texts using the new templates at the earliest opportunity. · p. 1 · High · Source
Submission of changes if content is altered
Appropriate application must be submitted
Applies to: When content changes are made
This editorial change can be made independently unless changes have been made to the content of the texts. In these cases, an appropriate application must be submitted. · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Full briefing

Practical implication

MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

Swissmedic mandates that updated templates for Patient Information and Information for Healthcare Professionals be utilized from 1 July 2026 for new submissions and variations. An optional section for instructions for use must be incorporated to enhance presentation and accessibility.

What changed: MAHs must use updated PI/FI templates for new submissions and variations, and incorporate the optional 'Gebrauchsanweisungen' section from 1 July 2026.

Why it matters: This change ensures that safety information and instructions for use are clearly presented, improving readability and user-friendliness for patients and healthcare professionals.

Practical implication: MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward